Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by DnB Asset Management AS

DnB Asset Management AS increased its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 18.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 12,132 shares of the biopharmaceutical company’s stock after acquiring an additional 1,889 shares during the quarter. DnB Asset Management AS’s holdings in Ultragenyx Pharmaceutical were worth $510,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC increased its stake in shares of Ultragenyx Pharmaceutical by 259.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 493 shares in the last quarter. Human Investing LLC acquired a new stake in Ultragenyx Pharmaceutical in the 4th quarter worth about $42,000. Van ECK Associates Corp increased its stake in Ultragenyx Pharmaceutical by 18.4% during the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 273 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Ultragenyx Pharmaceutical during the third quarter valued at approximately $83,000. Finally, Nomura Asset Management Co. Ltd. purchased a new position in shares of Ultragenyx Pharmaceutical in the third quarter valued at approximately $93,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

RARE has been the subject of several recent research reports. Wedbush reissued a “neutral” rating and issued a $48.00 price objective (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. Canaccord Genuity Group raised their price target on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a research note on Tuesday, February 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. HC Wainwright reiterated a “buy” rating and issued a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. Finally, Wells Fargo & Company boosted their target price on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a report on Friday, December 20th. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, Ultragenyx Pharmaceutical has an average rating of “Moderate Buy” and an average target price of $92.79.

Insider Activity

In related news, CEO Emil D. Kakkis sold 73,434 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total transaction of $3,091,571.40. Following the sale, the chief executive officer now directly owns 641,731 shares of the company’s stock, valued at $27,016,875.10. This represents a 10.27 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Theodore Alan Huizenga sold 967 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total transaction of $40,710.70. Following the completion of the transaction, the chief accounting officer now directly owns 50,265 shares of the company’s stock, valued at $2,116,156.50. This represents a 1.89 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 124,643 shares of company stock valued at $5,256,268. 5.80% of the stock is currently owned by corporate insiders.

Ultragenyx Pharmaceutical Price Performance

NASDAQ RARE opened at $35.37 on Thursday. The stock has a market capitalization of $3.32 billion, a P/E ratio of -5.58 and a beta of 0.61. The firm’s 50-day moving average is $41.26 and its two-hundred day moving average is $46.37. Ultragenyx Pharmaceutical Inc. has a 12 month low of $33.53 and a 12 month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The company had revenue of $164.88 million during the quarter, compared to analyst estimates of $163.23 million. As a group, analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.